Drug intelligence / Profile preview

GLPG1792

Development stage: Unknown
Lead developer: Galapagos
Modality: Small Molecules

Overview

GLPG1792 is an investigational small molecule developed by Galapagos in alliance with Servier for the treatment of osteoarthritis. Limited public data is available on its mechanism of action, indications beyond osteoarthritis, or clinical progress, with mentions primarily in company financial updates indicating early-stage development as of 2018.

Targets

ADAMTS5 (A disintegrin and metalloproteinase with thrombospondin motifs 5)

Beyond the preview

Go deeper on GLPG1792.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLPG1792.

Explore the full profile